-
1 Comment
China National Accord Medicines Corporation Ltd is currently in a long term uptrend where the price is trading 1.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.1.
China National Accord Medicines Corporation Ltd's total revenue rose by 27.3% to $17B since the same quarter in the previous year.
Its net income has increased by 30.8% to $404M since the same quarter in the previous year.
Finally, its free cash flow fell by 169.3% to $-586M since the same quarter in the previous year.
Based on the above factors, China National Accord Medicines Corporation Ltd gets an overall score of 4/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | HKD |
| ISIN | CNE0000009M8 |
| Sector | Healthcare |
| Industry | Medical Distribution |
| Target Price | 47.54 |
|---|---|
| Beta | 0.36 |
| PE Ratio | 8.96 |
| Dividend Yield | 6.8% |
| Market Cap | 13B |
China National Accord Medicines Corporation Ltd. engages in the retail and distribution of pharmaceutical products in China and internationally. It offers drugs, medical equipment, cargo transportation, warehousing, loading and unloading, glass instruments, cosmetics, sales of daily necessities, other business services, and other professional consulting services; agent services; and house leasing services. The company is also involved in the import and export of proprietary Chinese medicines, chemical preparations, antibiotics, biochemical drugs, biological preparations, diagnostic drugs, therapeutic and diagnostic biological products, packaged foods, chemical products, house supplies, and self-operated technologies. In addition, it engages in the retail and distribution of medical devices, as well as wholesale and retail of health supplies, etc. The company was formerly known as Shenzhen Health Mineral Water Corp., Ltd. The company was incorporated in 1993 and is headquartered in Shenzhen, China. China National Accord Medicines Corporation Ltd. operates as a subsidiary of Sinopharm Group Co., Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 200028.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
